**Curriculum Vitae Wenche SjursenName:** Wenche Sjursen**Born:**  22.04.59**Marital status:** Married, two children**Nationality:** Norwegian

**Occupation:** Associate professor; Molecular geneticists/ Scientist**Address:** Department ofPathology and Medical Genetics, St. Olavs Hospital,

Erling Skjalgsons gt. 1, 7006 Trondheim, Norway

# Private: Lillegårdsbakken 40, N-7016 Trondheim, NorwayEducation:1980 Bioengineer, Sør-Trøndelag University College

1986 Cand. mag. in chemistry, Chemical Institute, AVH, UNIT1989 Cand. scient in biochemistry, Chemical Institute, AVH, UNIT1996 Dr. scient in biochemistry, Chemical Institute, NTNU

**Work experience:**1981 Bioengineer at Molde Hospital1981-85 Bioengineer at St Olavs University Hospital1987 Maternity leave (5 months)1989 Research assistant at Chemical Institute, AVH, UNIT 1989-91 Research assistant at Institute of Biotechnology, NTH, UNIT1990-91 Maternity leave (10 months)1991-96 Research fellow at UNIGEN, Center of Molecular biology, NTNU

* 1. Associate professor, Institute of Biology, NTNU (6 months)

1997-2001 Associate professor at Institute of Bioengineer,Sør-Trøndelag University College

* 1. Leave of absence because of stay abroad (17 months) in Houston, Texas, USA

2001- Molecular geneticists/ Scientist at Department ofPathology and Medical Genetics,

St. Olavs University Hospital, Trondheim, 50%

2006- Associate professor at LBK, DMF, NTNU, 50%

**Experience with teaching and supervision:**

* Educational training:
	+ Two semester course in university pedagogic (UNIPED)
	+ Courses in PBL and TBL supervision at The medical faculty, NTNU
* Teaching experience:
	+ Research assistant at NTNU
	+ Associate professor at Institute of Bioengineer,Sør-Trøndelag University College and LBK, DMF, NTNU
		- Lectures for bachelor, master, medical doctors and PhD students
	+ Internal lectures at St. Olavs Hospital including twice the Friday lecture
	+ Lecturing in courses for medical doctors under specialization (genetics and pathology)
	+ Invited speaker, Newcastle, Australia, September 2013
* Experience as supervisor:
	+ Principal supervisor for 14 MSc students and one diploma student at NTNU; supplementary supervisor for several MSc and diploma students
	+ Principal supervisor for two and supplementary supervisor for one PhD students
	+ Principal supervisor for 17 bachelor projects (bioengineer students HiST)
* Experience as external examiner:
	+ About 40 MSc thesis in Trondheim, Oslo and Tromsø
	+ Different courses in cell biology, molecular biology, genetics, immunology etc. at NTNU and HiST
	+ One research training medicine (forskerlinje) student at NTNU
	+ PhD critic opponent (1 x second; 3 x third). Asked to be first opponent Fall 2015

**Research experience:**

* Previous:
	+ 1987-89: MSc student
	+ 1991-96: PhD student
	+ 1997-99: research in the ”Phospholipase A2” group, NTNU
	+ 2000-01: research projects at St Olavs Hospital, Department of medical genetics
	+ 2004-2012: project manager of “Identification of genetic factors involved in pheochromocytoma in the Norwegian population”
* Present:
	+ Research in inherited cancer:
		- Project coordinator of ”Colorectal cancer in Mid-Norway; identification of hereditary and non inherited subtypes”
		- ”Exome sequencing to identify high risk gene variants in a family predisposed to colorectal cancer”
		- Clinical research regarding diagnostic genetic testing of hereditary colorectal cancer and other hereditary cancer types
		- Collaboration with Bente Talseth-Palmer and Rodney Scott, Newcastle University, Australia: 4 weeks stay in their lab Autumn 2014

**Boards and committees:**

Chairman of the board for Norwegian society for human genetics (2007-2012)

Board member Norwegian group for inherited cancer (from 2009)

Member of the “European Mismatch Repair working group” (from 2011)

Member of different working groups forNorwegian society for human genetics

Member of committees for evaluation of applicants for jobs as associate professor (Oslo College, HiST, UiT)

**Peer reviewer in:**

Journal of Translational Medicine Research

” The Bioengineer”

**Publications:**

* **Sjursen, W**., "Synthesis of Chiral Compounds by biocatalysis by oksidoreductases from *Clostridium pasteurianum*", MSc Thesis, AVH, UNIT, Trondheim, 1989.
* Andersen, S., **Sjursen, W**., Lægreid, A., Volden, G. and Johansen, B., "Elevated Expression of Human Non-pancreatic Phospholipase A2 in Psoriatic Tissue", Inflammation, 18, 1-12, 1994.
* Andersen, S., **Sjursen, W**., Lægreid, A., Austgulen, R. and Johansen, B., "Immunohistologic Detection of Non-Pancreatic Phospholipase A2 (Type II) in Human Placenta and its Possible Involvement in Normal Parturition at Term", Prostaglandins Leukotrienes and Essential Fatty Acids, 51, 19-26, 1994
* Johansen, B., Andersen, S., **Sjursen, W.** and Lægreid, A., “Role of regulatory phospholipase A2 in inflamed human skin”, J. Cellular Biochemistry, suppl. 18D, 63, 1994
* **Sjursen, W**., “Phospholipase A2 in inflammatory mechanisms in skin and placental tissue” PhD Thesis, NTNU, 1996
* Johansen, B., Andersen, S., **Sjursen, W**., Gundersen, P. and Selbo, P.K. “Phospholipase A2 in psoriasis” i ”Phospholipase A2. Basic and clinical aspects in inflammatory diseases”, Progress in Surgery, Basel, Karger, 24, 225-231, 1997
* Frøyland, L., Madsen, L., **Sjursen, W**., Garras, A., Lie, Ø., Songstad, J., Rustan, A. C., og Berge, R. K., ”Effect of 3-thia fatty acids on the lipid composition of rat liver, lipoproteins and heart”, J. Lipid. Res. 38:1522-1534, 1997
* Thommessen. L., **Sjursen, W**., Gåsvik, K., Hanssen, W., Brekke, O.L., Skattebøl, L., Holmeide, A. K., Espevik, T., Johansen, B. and Lægreid, A., ” Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor Nuclear Factor-(B and expression of ICAM-1”, J. Immunology 161: 3421-3430, 1998
* **Sjursen, W.,** Brekke, O.L. og Johansen, B., ”Secretory and cytosolic phospholipase A2 regulate the long term cytokine induced eicosanoid production in human keratinocytes”, Cytokine Vol. 12, No. 8, 1189-1194, 2000
* Johansen, B., Anthonsen, M.W., Solhaug, A., **Sjursen, W**. and Andersen, S., “Molecular inflammatory mechanisms in human skin: Identification of drug targets.”*Chimie nouvelle* 76(19):3349-3350, 2001.
* Johansen, B., Anthonsen, M.W., **Sjursen, W**., Holmeide, A.K. and Skattebøl, L. “Trifluormethyl ketone phospholipase A2 inhibitors”. United Kingdom Patent appln. No. 0202002.2, priority date: 29. january 2002.
* Johansen, B., Anthonsen, M.W., **Sjursen, W.,** Holmeide, A.K. and Skattebøl, L., “Trifluormethyl ketone phospholipase A2 inhibitors”. International patent application no. PCT/GB03/00363. Priority date 29 jan. 2003.
* Tranø G, Wasmuth HH, **Sjursen W**, Hofsli E, Vatten LJ. ” Awareness of heredity in colorectal cancer patients is insufficient among clinicians: a Norwegian population-based study”, Colorectal Dis. Jun;11(5):456-61. 2009
* **Sjursen, W**., Bjørnevoll, I, Engebretsen L. F., Fjelland K., Halvorsen, T., Myrvold, H. A., “A Homozygote Splice Site PMS2 Mutation as Cause of Turcot Syndrome Gives Rise to two Different Abnormal Transcripts”, Fam Cancer, 8(3):179-86, 2009
* Tranø G, **Sjursen W**, Wasmuth HH, Hofsli E, Vatten LJ, “Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study ”, Br J Cancer Feb 2;102(3):482-8, 2010
* **Wenche Sjursen**, Bjørn Ivar Haukanes, Eli Marie Grindedal, Astrid Stormorken, Lars F. Engebretsen, Christoffer Jonsrud,Inga Bjørnevoll, Per Arne Andresen, Sarah Adriansen, Liss Anne Lavik, Bodil Gilde, Per Knappskog, Torunn Fiskerstrand, Eldbjørg Hanslien, Lovise Mæhle, Pål Møller, ”Current clinical criteria for Lynch syndrome are insensitive to identify MSH6 mutation carriers”, J Med Genet, 47:579-585, 2010
* May-Britt Tessem, M. B., Selnæs, K. M., **Sjursen, W**., Tranø, G., Giskeødegård, G. F., Bathen, T. F., Gribbestad, I. S., Hofsli, E., “Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis”, Journal of Proteome Research, Jul 2; 9(7):3664-70, 2010
* Tranø G, Wasmuth HH, **Sjursen W**, Vatten LJ. ”Patient and Tumour Characteristics That May Arise Clinicians’ Awareness of Familial Colorectal Cancer: A Norwegian, Population based study“, Scand J Gastroenterol. 2011 Oct;46(10):1236-42
* **Sjursen, W.,** Halvorsen, H., Hofsli, E., Bachke, S, Berge, Å., Engebretsen, L.F., Falkmer, S.E., Falkmer, U.G. and Varhaug, J.E. “Mutation Screening in a Norwegian Cohort with Pheochromocytoma”, Fam Cancer, Publ online 14 Feb 2013, DOI 10.1007/s10689-013-9608-0
* Hofsli E, **Sjursen W,** Prestvik WS, Johansen J, Rye M, Tranø G, Wasmuth H, Hatlevoll I, Thommesen L, “Identification of serum microRNA profiles in colon cancer”, Br J Cancer. 2013 Apr 30;108(8):1712-9. doi: 10.1038/bjc.2013.121. Epub 2013 Apr 4.
* Hansen M, Neckmann U, Lavik LA, Vold T, Gilde B, Toft RK and **Sjursen W**, “A massive parallel sequencing workflow for diagnostic genetic testing of mismatch repair genes”, Molecular Genetics & Genomic Medicine, March 2014, Volume 2, Issue 2, 86–200,
* Grindedahl E, Mæhle L, Bjørnevoll I, Stormorken A, Røyset E, Aarset H, Herlofson C, Medvik H, Møller P and **Sjursen W**, “The Norwegian PMS2 founder mutation c.989-1G>T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry”, Hereditary Cancer in Clinical Practice 2014 Apr 21;12(1):12
* Reimers A, **Sjursen W**, Helde G, Brodtkorb E. “Frequencies of UGT1A4\*2 (P24T) and \*3 (L48V) and their effects on serum concentrations of lamotrigine.”, Eur J Drug Metab Pharmacokinet, 2014 Des 10 [Epub ahead of print], PMID: 25492569
* Hansen MF, Johansen J, Bjørnevoll I, Sylvander AE, Steinsbekk KS, Sætrom P, Sandvik AK, Drabløs F, **Sjursen W**, “A Novel POLE Variant Associated with Cancers of Colon, Pancreas, Ovaries and Small Intestine", Familial Cancer, 2015 Apr 10. [Epub ahead of print], PMID: 25860647
* Eva Kathrine Svaasand, Lars Fredrik Engebretsen, Trond Ludvigsen, Wenche Brechan, **Wenche Sjursen**, “Novel deep intronic mutation introducing a cryptic exon found in a family with extensive NF1 phenotype”, Manuscript to be submitted
* Bente A. Talseth-Palmer, Denis C. Bauer, **Wenche Sjursen**, Tiffany J. Evans, Mary McPhillips, Anthony Proietto, Geoffrey Otton, Allan D. Spigelman and Rodney J. Scott, “Targeted next-generation sequencing identifies two Lynch syndrome families and a polygenic interaction that may cause cancer development in a third Lynch syndrome family”, Submitted to Journal of Clinical Oncology
* **Wenche Sjursen**, Mary McPhillips, Rodney Scott and Bente Talseth-Palmer, “Lynch syndrome mutation spectrum in New South Wales, Australia, including 60 novel mutations”, Manuscript to be submitted

# Popular science publications

* Eva Svaasand, **Wenche Sjursen**, Wenche S. Prestvik and Ingrid Eftedal, „Diagnostics of numerical chromosomal aberrations by fluorescence labelled microsatellite analyses“, The Bioengineer, no. 10, 2002, p.4-7
* Anne Lise Aakervik (Ingrid Eftedal og **Wenche Sjursen**), ”More individuals get help by gene testing”, Pharmaceuticals and Society, no. 5, August 2004, p. 54-55
* Liss Anne Lavik, Bodil Gilde and **Wenche Sjursen**, ”Molecular genetic testing when inherited colorectal cancer is suspected”, The Bioengineer, no. 10, 2004, p. 8-10
* Eva Hofsli and **Wenche Sjursen**, ”Markers of significance for diagnosis and treatment of intestinal cancer”, The Bioengineer, no. 4, 2009, p. 6-10
* Liss Anne Solberg Lavik **and** **Wenche Sjursen,** ” Molecular genetic analysis in investigation of hereditary colorectal cancer”, The Bioengineer, no. 6-7, 2009, p. 6-13

**Abstracts and posters:**

Written or oral presentations in 45 different national and international scientific meetings